Fox Chase Cancer Center (FCCC) has a well-established strategic management planning process and formally produced five-year strategic and financial plans since 1985. These result in rolling five-year recruitment, resource development, and implementation plans which, after review by the Center's External Advisory Board, are approved by the Center Board of Directors. As part of the change in Center leadership during the current CCSG cycle, a comprehensive strategic planning process was launched under the direction of Associate CCSG Director for Academics J. Robert Beck, Wl.D. This is discussed fully in this section of the grant as well as in the """"""""Overall Description of the Cancer Center"""""""" and """"""""Developmental Funds"""""""" sections. The plan incorporates Center mission, vision, and values, as well as 13 Strategic Objectives. Targeted recruitment to each of the five CCSG Research Programs and a balance of individual investigation and team science are Critical Success Factors for the two Discovery Objectives in the Plan. No CCSG funds are requested for this planning effort. CCSG funds are requested for two aspects of our evaluation efforts. First, we seek support for our six external advisory boards, five of which provide review and advice to each of our scientific Programs. The sixth, the President's External Advisory Board, is comprised of national leaders in cancer research and NCI designated Cancer Center directors. These External Advisory Boards have been actively involved in our decisions to reconfigure existing or develop new Shared Facilities. They also provide advice on reconfiguration of existing CCSG Programs as well as the balance of team science and individual investigation. The second request is for partial support for our annual daylong Scientific Retreat where members from all five Programs and our clinical investigators meet and discuss opportunities for translational research as well as a broad-range of cancer-related scientific collaborations.

Public Health Relevance

Strategic planning is a necessary process to ensure future success and growth of cancer research. Evaluation both with internal and via External Advisory Boards is necessary to ensure that goals are achieved in an effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475330
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$28,266
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336

Showing the most recent 10 out of 1280 publications